top of page

IDRI submits dossier for phase IIB testing of ID93+GLA-SE vaccine

The clinical dossier for a phase IIB, double-blind, randomized clinical trial to evaluate the safety and tolerability of ID93+GLA-SE as an adjunct to standard TB treatment has been prepared and submitted on 1st June 2019 by STriTuVaD partner IDRI, Infectious Disease Research Institute. They also revised a protocol for evaluating the safety, tolerability, and immunogenicity of the ID93+GLA-SE vaccine administered to HIV-negative patients during multidrug therapy for drug susceptible and drug resistant pulmonary tuberculosis, as well as development of an in silico database for predicting clinical outcomes as a primary objective. This protocol was submitted to the Drug Controller General of India's office on October 2019.

41 views0 comments

Recent Posts

See All


bottom of page